In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate

Drug Metabolism and Drug Interactions

Volumn 24, Issue 2-4, 2009, Pages 195-209

  Persiani, Stefano ^a   Canciani, Luca ^a   Larger, Patrice ^a   Rotini, Roberto ^a   Trisolino, Giovanni ^a   Antonioli, Diego ^a   Rovati, Lucio C ^a  

^a Rotta Research Laboratorium   (Italy)

Author keywords

Crystalline glucosamine sulfate; Drug drug interactions; Human P450 induction; Human P450 inhibition

Indexed keywords

CRYSTALLIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; GLUCOSAMINE SULFATE; KETOCONAZOLE; MESSENGER RNA; QUINIDINE; RECOMBINANT ENZYME; SULFAPHENAZOLE; TRANYLCYPROMINE;

ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYOPRESERVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 77950625898     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2009.24.2-4.195     Document Type: Article

References (29)

1. Altman RD, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 28: 1039-1049.
2. McAlindon TE, La Valley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469-1475. (Pubitemid 30151826)
3. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. A comprehensive meta-analysis. Arch Int Med 2003; 163: 1514-1522.
4. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G. Glucosamine therapy for treating osteoarthritis. Cochrane Database System Rev 2005; (2): CD002946.
5. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-256. (Pubitemid 32120855)
6. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113-2123. (Pubitemid 35168220)
7. Pavelka K, Bruyere O, Rovati LC, Olejárova M, Giacovelli G, Reginster JY. Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthritis Cartilage 2003; 11: 730-737. (Pubitemid 37184491)
8. Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, Giacovelli G, Reginster JY. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 2004; 11: 138-143. (Pubitemid 40353230)
9. Herrero-Beaumont G, Ivorra JAR, Trabado MDC, Blanco FJ, Benito P, Martìn-Mola E, Paulino J, Marenci JL, Porto A, Laffon A, Araùjo D, Figueroa M, Branco J. Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms against placebo and acetaminophen: the Glucosamine Unum In Die Efficacy (GUIDE) trial. Arthritis Rheum 2007; 56: 555-567.
10. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. Arzneim Forsch Drug Res 2001; 51: 699-725. (Pubitemid 32889393)
11. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
12. Kuhlmann J, Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Safety 2001; 24: 715-725. (Pubitemid 32848351)
13. Persiani S, Larger P. Strategies to assess the drug interaction potential in translational medicine. Exp Opin Drug Metab Toxicol 2006; 2: 675-686. (Pubitemid 46118316)
14. Davit B. FDA evaluation using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labelling. J Clin Pharmacol 1999; 39: 899-910. (Pubitemid 30644025)
15. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. Br J Clin Pharmacol 2001; 52: 107-117. (Pubitemid 32862777)
16. Rodrigues AD. Commentary: Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem Pharmacol 1994; 48: 2147-2156. (Pubitemid 24374702)
17. Obach S, Walsky R, Venkatakrishnan K, Houston B, Tremaine L. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationship, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005; 78: 852-1592
18. Dept. of Health and Human Services, U.S. Food and Drug Administration, CDER, CBER. Guidance for industry. Drug metabolism/drug interaction studies in the drug development process: studies in vitro, 1997.
19. EMEA. Note for guidance on the investigation of drug interactions. CPMP/EWP/560/95, 1997.
20. Dept. of Health and Human Services, U.S. Food and Drug Administration, CDER, CBER. Guidance for industry. In vivo drug metabolism/drug interaction studies. Study design, data analysis, and recommendations for dosing and labelling, 1999.
21. Dept. of Health and Human Services, U.S. Food and Drug Administration, CDER, CBER. Guidance for industry. Drug interaction studies-study design, data analysis, and implication for dosing and labelling, September 2006.
22. FDA U.S. Dept. of Health and Human Services. Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html, 2004.
23. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005; 13: 1041-1049. (Pubitemid 41672501)
24. Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, Paganini D, Antonioli D, Roda A. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulfate at therapeutic dose. Osteoarthritis Cartilage 2007; 15: 764-772. (Pubitemid 46888164)
25. Donato MT, Jiménez N, Castell J, Gòmez-Lechòn M. Fluorescence-based assay for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos 2004; 32: 699-706.
26. Nomeir A, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR, Silber P, Lin CC. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 2001; 29: 748-753. (Pubitemid 32374578)
27. Roymans D, Annaert P, Van Houdt J, et al. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 2005; 33: 1004-1016. (Pubitemid 41002783)
28. Baldwin S, Bramhall JL, Ashby CA, Murdock PR, Hood SR, Ayrton AD, Clarke S. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse tanscriptase-polymerase chain reaction. Drug Metab Dispos 2006; 34: 1063-1069.
29. Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, Brown AM. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 2000; 28: 781-788. (Pubitemid 30470828)